Mattei, J.C.; Bouvier-Labit, C.; Barets, D.; Macagno, N.; Chocry, M.; Chibon, F.; Morando, P.; Rochwerger, R.A.; Duffaud, F.; Olschwang, S.;
et al. Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular Profile. Cancers 2020, 12, 583.
https://doi.org/10.3390/cancers12030583
AMA Style
Mattei JC, Bouvier-Labit C, Barets D, Macagno N, Chocry M, Chibon F, Morando P, Rochwerger RA, Duffaud F, Olschwang S,
et al. Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular Profile. Cancers. 2020; 12(3):583.
https://doi.org/10.3390/cancers12030583
Chicago/Turabian Style
Mattei, Jean Camille, Corinne Bouvier-Labit, Doriane Barets, Nicolas Macagno, Mathieu Chocry, Frédéric Chibon, Philippe Morando, Richard Alexandre Rochwerger, Florence Duffaud, Sylviane Olschwang,
and et al. 2020. "Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular Profile" Cancers 12, no. 3: 583.
https://doi.org/10.3390/cancers12030583
APA Style
Mattei, J. C., Bouvier-Labit, C., Barets, D., Macagno, N., Chocry, M., Chibon, F., Morando, P., Rochwerger, R. A., Duffaud, F., Olschwang, S., Salas, S., & Jiguet-Jiglaire, C.
(2020). Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular Profile. Cancers, 12(3), 583.
https://doi.org/10.3390/cancers12030583